A decade-spanning review of monoclonal antibody therapies targeting amyloid plaques in Alzheimer’s disease patients concluded that the clinical benefit of such drugs is negligible, drawing swift and pointed criticism from researchers across the field, including several who had previously expressed skepticism about the drug class.

The review evaluated seven anti-amyloid monoclonal antibody drugs developed over approximately two decades. Its central claim: that the aggregate evidence does not support meaningful clinical improvement in patients with Alzheimer’s disease. That claim did not stand unchallenged. Multiple Alzheimer’s specialists objected to the methodological approach, arguing that collapsing seven pharmacologically distinct agents into a single analytical framework produced a conclusion that was, in the words of several critics, essentially meaningless.

The methodological dispute cuts to a familiar tension in evidence synthesis. Umbrella reviews and pooled analyses gain statistical power at the cost of granularity. When the drugs under review operate through different mechanisms or bind to distinct amyloid species, lumping their outcome data together can obscure real signal. That appears to be the core objection here.

Two drugs drew particular attention. Leqembi and Kisunla, the two most recent agents among the seven reviewed, produced data showing measurable slowing of cognitive decline in their respective clinical trials. Both received U.S. regulatory approval on that basis. Both are currently available to patients. Critics of the review said that the negative aggregate finding effectively buried this signal, which had already cleared the U.S. Food and Drug Administration’s evidentiary threshold for approval.

“The data from Leqembi and Kisunla showed they could slow cognitive decline,” one expert told STAT News, framing the review’s methodology as the central problem rather than the underlying science.

The dispute isn’t merely academic. Leqembi and Kisunla represent the only anti-amyloid drugs currently accessible to patients in the United States. If the review’s framing gains traction in payer and formulary decision-making, coverage decisions could follow. That possibility alone warrants careful scrutiny of the review’s design.

---

Methodological Concerns Merit Attention Before Conclusions Are Drawn

The review’s scope was broad: a decade of research, seven drugs, trials of varying sizes and durations, and patient populations that likely differed on key disease-stage variables. Anti-amyloid therapies do not constitute a monolithic drug class. Earlier agents, most of which failed to reach regulatory approval, targeted amyloid through mechanisms and at disease stages that differed considerably from the approaches used in Leqembi and Kisunla trials. Averaging across that heterogeneity produces a number. It doesn’t necessarily produce insight.

In meta-analytic literature across oncology and neurology, this problem is well documented. A pooled negative result drawn from a mixture of failed early-stage compounds and more refined later-generation agents can mask the genuine efficacy of the latter. The Cochrane Collaboration has published methodological guidance on exactly this kind of heterogeneity problem, and reviewers are expected to address it directly. Whether the Alzheimer’s review in question did so adequately is the question driving the controversy.

Several of the dissenting experts had not been unconditional advocates for anti-amyloid therapy. Their skepticism was on record. The fact that even this group objected to the review’s methodology is notable. It suggests the criticism isn’t motivated purely by commercial or professional allegiance to the drugs in question.

Still, the review’s authors presumably had a rationale for their design choices. That rationale deserves examination. Criticism of a study’s conclusions should not substitute for a rigorous reading of its methods section, and the field would benefit from a direct response from the review’s authors addressing the heterogeneity objections specifically.

---

Drug Pricing: Senate Report Contradicts White House Claims

Separately, a report released by Sen. Bernie Sanders, I-Vt., the ranking member on the Senate Health, Education, Labor and Pensions (HELP) Committee, identified a substantial gap between the Trump administration’s stated drug pricing outcomes and observable market behavior. The report was released ahead of a HELP Committee hearing on prescription drug prices.

Sen. Sanders’ report found that pharmaceutical companies that signed pricing deals with the Trump administration had raised the cost of hundreds of medications. New drugs launched by those same companies carried an average price of $353,000 per year. The categories involved included gene therapies, cancer medications, and multiple sclerosis drugs. That’s not a marginal adjustment in either direction. A $353,000 annual average launch price represents a structural feature of how high-cost specialty therapies reach the market, and it sits uneasily alongside claims that negotiated deals have produced consumer savings.

The report also identified combined profits of $177 billion among the companies that had signed deals with the administration during President Trump’s second term, up from $107 billion the preceding year. The $70 billion increase in profits doesn’t confirm that pricing deals were ineffective, but it does complicate the narrative that such deals imposed meaningful discipline on pricing behavior. Profit increases of that magnitude can reflect factors other than drug prices, including volume, pipeline launches, and operational efficiencies. But they are difficult to square with the premise that manufacturers absorbed real concessions.

The Senate HELP Committee has jurisdiction over legislation governing pharmaceutical pricing and the scope of federal drug negotiation authority, making this report consequential for any forthcoming legislative action.

---

FDA and Compounded Peptides

A third area of active regulatory attention involves the Food and Drug Administration’s (FDA) interest in compounded peptides. Compounding pharmacies have expanded their peptide-based offerings considerably, and the FDA has been examining whether existing oversight frameworks are adequate for this product category. The peptides at issue are not standard small-molecule generics. They represent a class of compounds where manufacturing quality, stability, and clinical evidence vary considerably across compounders.

Compounded drugs generally exist outside the standard approval pathway and are therefore not subject to the same pre-market efficacy and safety reviews that govern approved products. For peptides specifically, this creates a risk profile that differs from conventional compounded formulations. Peptide synthesis requires specialized manufacturing controls, and contamination or degradation risks can be clinically consequential.

FDA scrutiny of this area doesn’t necessarily lead to prohibition. It can lead to clearer guidance, facility inspections, or reclassification of specific peptides as biologics or drugs subject to different compounding restrictions. The outcome of that regulatory interest will have direct implications for practitioners who currently recommend or prescribe compounded peptide therapies, including those used in weight management, regenerative contexts, and other applications that have grown in clinical currency over the past several years.

---

The Broader Pricing Environment

The Sanders report and the Alzheimer’s drug review, though arising from entirely different domains, share a common thread. Both raise questions about the relationship between regulatory approval, clinical evidence quality, and the prices patients ultimately pay.

Leqembi carries a list price of approximately $26,500 per year. Kisunla’s pricing falls in a comparable range. For drugs whose clinical benefit is disputed by at least one systematic review, those price points will attract ongoing scrutiny from payers, including the Centers for Medicare and Medicaid Services (CMS), which now has expanded negotiation authority under existing federal law. If the anti-amyloid drug review gains methodological credibility, it will likely be cited in CMS value assessments and by pharmacy benefit managers evaluating formulary placement.

That dynamic can’t be separated from the question of what the review actually shows. A flawed negative finding that incorrectly minimizes therapeutic benefit would be harmful to patients who might benefit from Leqembi or Kisunla. A valid negative finding that identifies overpromising in the anti-amyloid field would serve the public interest. The field needs to determine which of those it is facing.

What can be said with confidence is that the randomized controlled trial (RCT) evidence supporting Leqembi and Kisunla was sufficient for FDA approval, that the review’s pooling methodology has drawn substantial expert objection on technical grounds, and that no single systematic review should be treated as the final word on a drug class of this complexity. The review merits further investigation, including independent methodological critique and, where possible, reanalysis using subgroup-appropriate frameworks.

Sen. Sanders’ report and its $353,000 average launch price figure will be entered into the congressional record. Whether it moves legislative action on pricing reform depends on dynamics that extend well beyond the pharmacoeconomic data.

Both stories will continue.